Skip to content
The Policy VaultThe Policy Vault

Cotellic (cobimetinib)Medica

Melanoma (unresectable, advanced, or metastatic) with BRAF V600 mutation

Initial criteria

  • Patient is age ≥ 18 years
  • Patient has unresectable, advanced, or metastatic melanoma
  • Patient has BRAF V600 mutation-positive disease
  • Medication is prescribed in combination with Zelboraf (vemurafenib tablets)

Approval duration

1 year